Correct Answer: C. Chronic gout
Pegloticase is a recombinant uricase enzyme conjugated to polyethylene glycol (PEG), which catalyzes the oxidation of uric acid to allantoin—a more soluble and readily excretable metabolite. It is specifically indicated for refractory chronic gout in patients who have failed conventional urate-lowering therapy (allopurinol, febuxostat) or are intolerant to them. In India, where gout prevalence is rising due to urbanization and dietary changes, pegloticase is reserved for severe tophaceous gout with recurrent flares and joint damage. The enzyme rapidly lowers serum uric acid levels (often to <1 mg/dL within days), dissolving monosodium urate deposits and preventing further crystal-induced inflammation. It is administered as an intravenous infusion every 2 weeks. Pegloticase does not treat other crystal arthropathies because it specifically targets uric acid metabolism; it has no effect on pyrophosphate crystals or the inflammatory pathways in psoriatic or rheumatoid arthritis. Per KD Tripathi and standard rheumatology practice in India, pegloticase is a last-line urate-lowering agent for gout refractory to conventional therapy.
Why the other options are wrong
A. Psoriatic arthritis — Psoriatic arthritis is an inflammatory arthropathy driven by TNF-α and IL-17, not uric acid crystal deposition. Pegloticase has no role in lowering TNF or modulating T-cell responses. Treatment requires NSAIDs, DMARDs (methotrexate), or biologics (TNF inhibitors, IL-17 inhibitors)—not uricase. NBE may pair pegloticase with 'arthritis' to trap students unfamiliar with its specific uric acid mechanism. B. Rheumatoid arthritis — Rheumatoid arthritis is an autoimmune disease with immune complex deposition and synovial inflammation, not uric acid crystal disease. Pegloticase does not lower uric acid in RA patients and has no immunosuppressive or anti-TNF activity. RA is managed with DMARDs, biologics, and NSAIDs. The trap is confusing 'arthritis' terminology across different joint diseases. D. Calcium pyrophosphate dehydrate crystal deposition (CPPD) — CPPD (pseudogout) involves pyrophosphate crystals, not uric acid. Pegloticase degrades uric acid to allantoin and has zero effect on pyrophosphate crystal formation or dissolution. CPPD is managed with NSAIDs, colchicine, and intra-articular corticosteroids. This option exploits confusion between crystal arthropathies.
High-Yield Facts
- Pegloticase is a recombinant uricase that converts uric acid → allantoin (highly soluble, renal excretion).
- Indication: Refractory/tophaceous gout unresponsive to allopurinol, febuxostat, or due to intolerance.
- Dosing: 8 mg IV infusion every 2 weeks; rapidly achieves serum uric acid <1 mg/dL.
- Mechanism specificity: Works only on uric acid metabolism; no effect on other crystal arthropathies (CPPD, MSU in other contexts) or inflammatory arthropathies.
- Adverse effects: Infusion reactions, gout flares (managed with prophylactic colchicine/NSAIDs), antibody formation (loss of efficacy).
- Indian context: Reserved for severe tophaceous gout in urban populations with poor adherence or contraindications to conventional urate-lowering drugs.
Mnemonics
PEGU for Pegloticase PEG-uricase, Enzyme, Gout (refractory), Uric acid → allantoin. Use when asked 'what drug for refractory gout?' ULT Ladder (Urate-Lowering Therapy) 1st: Allopurinol/Febuxostat → 2nd: Add losartan/lesinurad → 3rd: Pegloticase (last resort). Helps recall pegloticase is final-line.
NBE Trap
NBE pairs pegloticase with multiple arthritis types to exploit students' confusion between crystal arthropathies (gout, CPPD) and inflammatory arthropathies (RA, psoriatic arthritis). The trap is assuming any 'arthritis drug' works for all joint diseases.
Clinical Pearl
In Indian urban practice, pegloticase is increasingly used in patients with tophaceous gout and chronic kidney disease (where conventional urate-lowering drugs are contraindicated or ineffective). A patient with tophi eroding through skin and recurrent flares despite allopurinol 800 mg daily is a classic pegloticase candidate—it can dissolve tophi within weeks, restoring function and quality of life.
_Reference: KD Tripathi Pharmacology Ch. 12 (Autacoids & Related Drugs); Harrison Ch. 386 (Gout & Crystal Arthropathies)_